India Pulmonary Drug Delivery Systems Market Outlook

india has a large and growing population, which is driving demand for pulmonary drug delivery systems in the country. according to research from the world health organization (who) in 2016, india has the second highest number of people living with asthma in the world, at 17 million people, with 2 million incident cases of chronic obstructive pulmonary disease (copd) recorded that same year. india is also the world’s leading consummers of generic drugs, a market which makes up approximately 40-45% of the total global generic drugs market. this makes india a rapidly growing market for pulmonary drug delivery systems. pulmonary drug delivery systems refer to thefacilities, technologies, and products used to administer drugs via inhalation or aerosol, rather than orally or intravenously. with their ability to get rapidly absorbed into the bloodstream, these systems are being used more and more in india to treat a wide variety of respiratory illnesses. these systems have also been an attractive option for the indian patient population due to the ease of administration and safety of these products. the major players in the indian pulmonary drug delivery system market are cipla, teva, and lupin, who together account for over 75% of the market share. recently, cipla and teva have launched generic asthma inhalers in india with a focus on cost-effective treatment. this has contributed to increasing public uptake of these products, which is driving the growth of the pulmonary drug delivery system market in india. the indian government is actively involved in promoting the development of this market. a number of international pharmaceutical companies, such as baxter, mendel and spi pharma have been granted permission to manufacture pulmonary drugs in india. these companies have made significant investments in the country and are looking to strengthen their position in the indian market. furthermore, organizations such as the global initiative for asthma (gina) are working to strengthen awareness and increase access to pulmonary drug delivery systems in india. their initiatives include training programs for doctors, setting up medication centers, and creating public awareness campaigns. in conclusion, the indian market for pulmonary drug delivery systems is expected to experience continued growth in the coming years as the prevalence of respiratory illnesses increases and international players continue to invest in the indian market. the availability of cost-effective treatments and public awareness campaigns are likely to drive further uptake of these systems in india.